| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biology, University of Maryland, Baltimore, MD 21250 This work was supported by National Institutes of Health Grant 1R01CA52527 and U.S. Army Medical Research and Materiel Command Grant DAMD17–94-J-4323.
We have developed and shown to be efficacious an immunotherapeutic strategy to enhance the generation of tumor-specific CD4+ T helper lymphocytes. The approach uses autologous tumor cells genetically modified to express syngeneic MHC class II genes as cell-based immunogens and is based on the hypothesis that tumor cells directly present tumor Ags to CD4+ T cells. Since the conventional pathway for CD4+ T cell activation is indirect via professional APC, induction of immunity following immunization with class II-transfected tumor cells was examined in bone marrow chimeric mice. Both tumor and host-derived cells are APC for tumor Ags, suggesting that the efficacy of tumor cell vaccines can be significantly improved by genetic modifications that enhance tumor cell Ag presentation.
This article has been cited by other articles:
|
|
 |
|
  J. J. Bosch, J. A. Thompson, M. K. Srivastava, U. K. Iheagwara, T. G. Murray, M. Lotem, B. R. Ksander, and S. Ostrand-Rosenberg MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells Cancer Res., May 1, 2007; 67(9): 4499 - 4506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Oldford, J. D. Robb, D. Codner, V. Gadag, P. H. Watson, and S. Drover Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients Int. Immunol., November 1, 2006; 18(11): 1591 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mortara, P. Castellani, R. Meazza, G. Tosi, A. De Lerma Barbaro, F. A. Procopio, A. Comes, L. Zardi, S. Ferrini, and R. S. Accolla CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory. Clin. Cancer Res., June 1, 2006; 12(11): 3435 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Dolan, K. D. Gibbs Jr., and S. Ostrand-Rosenberg Tumor-Specific CD4+ T Cells Are Activated by "Cross-Dressed" Dendritic Cells Presenting Peptide-MHC Class II Complexes Acquired from Cell-Based Cancer Vaccines J. Immunol., February 1, 2006; 176(3): 1447 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Thompson, S. K. Dissanayake, B. R. Ksander, K. L. Knutson, M. L. Disis, and S. Ostrand-Rosenberg Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4+ T Cells Whether or Not They Are Silenced for Invariant Chain Cancer Res., January 15, 2006; 66(2): 1147 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Guo, H. Niiya, T. Azuma, N. Uchida, Y. Yakushijin, I. Sakai, T. Hato, M. Takahashi, S. Senju, Y. Nishimura, et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner Blood, August 15, 2005; 106(4): 1415 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Dissanayake, N. Tuera, and S. Ostrand-Rosenberg Presentation of Endogenously Synthesized MHC Class II-Restricted Epitopes by MHC Class II Cancer Vaccines Is Independent of Transporter Associated with Ag Processing and the Proteasome J. Immunol., February 15, 2005; 174(4): 1811 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, S. Koido, M. Ohana, C. Liu, and J. Gong Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells J. Immunol., February 1, 2005; 174(3): 1274 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Dissanayake, J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy Cancer Res., March 1, 2004; 64(5): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Dolan, T. P. Phelan, D. Ilkovitch, L. Qi, W. F. Wade, T. M. Laufer, and S. Ostrand-Rosenberg Invariant Chain and the MHC Class II Cytoplasmic Domains Regulate Localization of MHC Class II Molecules to Lipid Rafts in Tumor Cell-Based Vaccines J. Immunol., January 15, 2004; 172(2): 907 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Becart, N. Setterblad, S. Ostrand-Rosenberg, S. J. Ono, D. Charron, and N. Mooney Intracytoplasmic domains of MHC class II molecules are essential for lipid-raft-dependent signaling J. Cell Sci., June 15, 2003; 116(12): 2565 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Muntasell, M. Carrascal, L. Serradell, P. v. Veelen, F. Verreck, F. Koning, G. Raposo, J. Abian, and D. Jaraquemada HLA-DR4 Molecules in Neuroendocrine Epithelial Cells Associate to a Heterogeneous Repertoire of Cytoplasmic and Surface Self Peptides J. Immunol., November 1, 2002; 169(9): 5052 - 5060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yasukawa, H. Ohminami, K. Kojima, T. Hato, A. Hasegawa, T. Takahashi, H. Hirai, and S. Fujita HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+ T lymphocytes Blood, September 1, 2001; 98(5): 1498 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Qi and S. Ostrand-Rosenberg H2-O Inhibits Presentation of Bacterial Superantigens, but Not Endogenous Self Antigens J. Immunol., August 1, 2001; 167(3): 1371 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Guilloux, X.-f. Bai, X. Liu, P. Zheng, and Y. Liu Optimal Induction of Effector but not Memory Antitumor Cytotoxic T Lymphocytes Involves Direct Antigen Presentation by the Tumor Cells Cancer Res., February 1, 2001; 61(3): 1107 - 1112. [Abstract] [Full Text]
|
|
|
|
|
|
L. Qi, J.-M. Rojas, and S. Ostrand-Rosenberg Tumor Cells Present MHC Class II-Restricted Nuclear and Mitochondrial Antigens and Are the Predominant Antigen Presenting Cells In Vivo J. Immunol., November 15, 2000; 165(10): 5451 - 5461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. Fedoseyeva, F. Boisgerault, N. G. Anosova, W. S. Wollish, P. Arlotta, P. E. Jensen, S. J. Ono, and G. Benichou CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice J. Immunol., June 1, 2000; 164(11): 5641 - 5651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Pulaski, D. S. Terman, S. Khan, E. Muller, and S. Ostrand-Rosenberg Cooperativity of Staphylococcal aureus Enterotoxin B Superantigen, Major Histocompatibility Complex Class II, and CD80 for Immunotherapy of Advanced Spontaneous Metastases in a Clinically Relevant Postoperative Mouse Breast Cancer Model Cancer Res., May 1, 2000; 60(10): 2710 - 2715. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. Tempero, M. L. VanLith, K. Morikane, G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth CD4+ Lymphocytes Provide MUC1-Specific Tumor Immunity In Vivo That Is Undetectable In Vitro and Is Absent in MUC1 Transgenic Mice J. Immunol., November 15, 1998; 161(10): 5500 - 5506. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
